ARQT

Arcutis Biotherapeutics, Inc.

• Simply Wall St·1d ago

  Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next

• Reuters·1d ago

  Palvella Therapeutics names Kent Taylor senior vice president of sales

• Reuters·5d ago

  Arcutis director Howard G. Welgus disposes of common shares worth $0.2 million

• NASDAQ·5d ago

  Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS

• Simply Wall St·04/01 21:24

  Assessing Arcutis Biotherapeutics (ARQT) Valuation After Positive ZORYVE Infant Phase 2 Trial Results

• Reuters·03/31 20:11

  Arcutis management to present at Needham Virtual Healthcare Conference fireside chat

• Benzinga·03/30 07:15

  Reported Saturday, Arcutis' Phase 2 INTEGUMENT-INFANT Trial Shows Zoryve Cream 0.05% Achieves 49% Clear Or Almost Clear Skin And 58.3% EASI-75 In Infants With Atopic Dermatitis

• NASDAQ·03/30 06:45

  Arcutis Reports New Positive Phase 2 Results For ZORYVE Cream In Infant Atopic Dermatitis

• Simply Wall St·03/30 02:04

  How New Infant Atopic Dermatitis Data And sNDA Plans At Arcutis (ARQT) Have Changed Its Investment Story

• TipRanks·03/29 14:30

  Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream

• Reuters·03/28 15:00

  Arcutis says Phase 2 trial shows Zoryve cream improves infant atopic dermatitis

• Simply Wall St·03/21 05:07

  Did New Long-Term Pediatric ZORYVE Data Just Shift Arcutis Biotherapeutics' (ARQT) Investment Narrative?

• Simply Wall St·03/19 06:08

  A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness

• TipRanks·03/18 12:20

  Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting

• Benzinga·03/18 12:06

  Arcutis Biotherapeutics To Present New Data From Its Clinical Development Program And Marketed ZORYVE Portfolio